Another weight-loss drug, survodutide, being developed by Boehringer Ingelheim, a German drug company, and Zealand, has shown promising results in being able to treat a serious liver condition called metabolic dysfunction-associated steatohepatitis (MASH).

另一种减肥药 Survodutide 是由德国制药公司勃林格殷格翰和 Zealand 共同开发的，在治疗一种名为代谢功能障碍相关脂肪性肝炎 (MASH) 的严重肝病方面已显示出良好的效果。

Waheed Jamal from Boehringer Ingelheim says that there is evidence that glucagon breaks down more fat in the liver compared with GLP-1 and reduces fibrosis (build-up of excessive scar tissue in the liver).

勃林格殷格翰公司的 Waheed Jamal 表示，有证据表明，与 GLP-1 相比，胰高血糖素能够分解肝脏中的更多脂肪并减少纤维化（肝脏中过多疤痕组织的堆积）。